参考文献/References:
[1]Siegel RL,Miller KD,Jemal A.Cancer statistics, 2020[J]. CA Cancer J Clin,2020,70(1):7-30.[2]蔡耿喜,蔡子杰,陈前军,等.乳腺癌新辅助化疗的现状与进展——南方乳腺癌论坛主要议题与共识[J].中国普通外科杂志,2019,28(11):1309-1321.[3]蒋丽君,张伟,钮晖,等.379例晚期恶性肿瘤患者凝血功能的改变及其临床意义[J].宁夏医科大学学报,2019,41(7):681-684.[4]夏兰兰,颜丙芳,赵红梅,等.卵巢癌患者凝血功能指标检测结果分析[J].检验医学与临床,2021,18(9):1294-1296.[5]迪娜·艾尼瓦尔,沙娅·玛哈提,肖蕾,等.190例肺癌患者凝血指标水平及其临床意义的研究[J].现代肿瘤医学,2019,27(21):3801-3805.[6]Yu M,Song Z,Xiaofei L,et al.Clinical and Prognostic Significance of Preoperative Plasma Fibrinogen Levels in Patients with Operable Breast Cancer[J].PLoS One,2016,11(1):e0146233.[7]Ghadhban BR.Plasma d-dimer level correlated with advanced breast carcinoma in female patients[J].Ann Med Surg (Lond),2018,36:75-78.[8]Wang L,Wang J,Li P,et al.Association between short-term heart rate variability and blood coagulation in patients with breast cancer[J].Sci Rep,2021,11(1):15414.[9]邵志敏,江泽飞,李俊杰,等.中国乳腺癌新辅助治疗专家共识(2019年版)[J].中国癌症杂志,2019,29(5):390-400.[10]Nguyen CV,Nguyen QT,VHT N,et al.Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis[J].Int J Clin Exp Pathol,2021,14(3):322-337.[11]Zhou Q,Dong J,Sun QQ,et al.Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis[J].BMJ Open,2021,11(9):e047957.[12]Colomer R,Saura C,Pedro Sánchez㏑ovira,et al.Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement[J].The Oncologist,2019,24(5):603-611.[13]Caudle AS,Gonzalez-Angulo AM,Hunt KK,et al.Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer[J].J Clin Oncol,2010,28:1821-1828.[14]Jarz?諭b M,Stobiecka E,Badora-Rybicka A,et al.Association of breast cancer grade with response to neoadjuvant chemotherapy assessed postoperatively[J].Pol J Pathol,2019,70(2):91-99.[15]Chen Y,Chen K,Xiao X,et al.Pretreatment neutrophil-tolymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study[J].BMC Cancer,2016,16:320.[16]Liu S,Duan X,Xu L,et al.Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2- positive breast cancer treated with trastuzumab- based neoadjuvant chemotherapy[J].Breast Cancer Res Treat,2015,154(2):239-249.[17]Falanga A,Russo L,Milesi V,et al.Mechanisms and risk factors of thrombosis in cancer[J].Crit Rev Oncol Hematol,2017,118:79-83.[18]Falanga A,Schieppati F,Russo D.Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable Stateof Patients with Cancer[J].Semin Thromb Hemost,2015,41(7):756-764.[19]Chew HK,Wun T,Harvey D,et al.Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers[J].Archives of Internal Medicine,2006,166(4):458-464.[20]Kitayama H,Kondo T,Sugiyama J,et al.384P Venous thromboembolism in hospitalized cancer patients receiving chemotherapy in a Japanese community hospital: A prospective observational study[J].Annals of Oncology,2015,26(Issue Supl.9):ix111-ix124.[21]Xue YC,Skretting G,Tinholt M,et al.A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7[J].Thrombosis Research,2017,157:111-116.[22]Yang WJ,Zhang GL,Cao KX,et al.A Hypercoagulable Hematological Metastasis Breast Cancer Model[J].Biomed Res Int,2021,2021:5473959.[23]D’Asti E,Anderson GM,Rak J.Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile[J].Biochem Biophys Res Commun,2017,494(3-4):700-705.[24]St?觟mpfli SF,Akhmedov A,Hausladen S,et al.Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients[J].Anticancer Res,2017,37(6):3259-3264.[25]Tinholt M,Garred ?覫,Borgen E,et al.Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer:the CoCaV study[J].J Thromb Haemost,2018,16(7):1347-1356.[26]van Westerloo DJ,Giebelen IAJ,Meijers JCM,et al.Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats[J].J Thromb Haemost,2006,4(9):1997-2002.[27]Kinnunen PT,Murto MO,Artama M,et al.Anticoagulants and Breast Cancer Survival: A Nationwide Cohort Study[J].Cancer Epidemiol Biomarkers Prev,2020,29(1):208-215.[28]Giaccherini C,Marchetti M,Masci G,et al.Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer[J].Haematologica,2020,105(6):1704-1711.[29]Hong D,Zhou H,Sun Y,et al.D-dimer as a potential clinical marker for predicting metastasis and progression in cancer[J].Biomed Rep,2018,9(5):453-457.[30]Mi XK,Liu QR,Zhu L,et al.Mechanism of the high coagulation state of breast cancer tissue factor[J].Eur Rev Med Pharmacol Sci,2017,21(9):2167-2171.[31]Wen J,Yang Y,Ye F,et al.The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment[J].Breast,2015,24(6):745-750. [32]Graf ME,Sookthai D,Johnson T,et al.Pre-diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study[J].Int J Cancer,2018,143(11):2659-2667.[33]Okano M,Oshi M,Butash AL,et al.Estrogen receptor positive breast cancer with high expression of androgen receptor has less cytolytic activity and worse response to neoadjuvant chemotherapy but better survival[J].Int J Mol Sci,2019,20(11):2655.[34]Klein J,Tran W,Watkins E,et al.Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy:a retrospective cohort analysis[J].BMC Cancer,2019,19(1):306.[35]Kim KI,Lee KH,Kim TR,et al.Ki 67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients[J].J Breast Cancer,2014,17(1):40-46.[36]Tan S,Fu X,Xu S,et al.Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy[J].Pathol Oncol Res,2021,27:1609972.[37]Prat A,Fan C,Fernandez A,et al.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy[J].BMC Med,2015,13:303.[38]潘婉婉,董孟浩,余发智,等.外周血炎症指标NLR、PLR、LMR预测乳腺癌新辅助化疗疗效的价值[J].中华全科医学,2021,19(9):1442-1446.[39]Mei Y,Liu H,Sun X,et al.Plasma fibrinogen level may be a possible marker for the clinical response and prognosis of patients with breast cancer receiving neoadjuvant chemotherapy[J].Tumour Biol,2017,39(6):1010428317700002. [40]Wang YH,Wang Y,Chen R,et al.Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients[J].BMC cancer,2021,21(1):542.
相似文献/References:
[1]屈欣然.DCE-MRI对局部进展期乳腺癌新辅助化疗的临床指导价值研究[J].医学信息,2018,31(04):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
QU Xin-ran.Clinical Value of DCE-MRI in Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer[J].Journal of Medical Information,2018,31(16):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
[2]董 云.SPECT/CT 双时相99mTc- MIBI断层显像
在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(16):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Journal of Medical Information,2018,31(16):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与
健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Journal of Medical Information,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[6]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,31(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Journal of Medical Information,2018,31(16):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[7]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,31(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(16):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[8]苏 志,吴 蔚,吴智钢,等.含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察[J].医学信息,2018,31(21):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
SU Zhi,WU Wei,WU Zhi-gang,et al.Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC[J].Journal of Medical Information,2018,31(16):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
[9]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Journal of Medical Information,2018,31(16):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[10]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,31(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Journal of Medical Information,2018,31(16):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[11]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2020,33(16):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
[12]陈甜甜,潘跃银,沈夏波.新辅助内分泌治疗与新辅助化疗用于乳腺癌中的短期疗效Meta分析[J].医学信息,2020,33(14):67.[doi:10.3969/j.issn.1006-1959.2020.14.020]
CHEN Tian-tian,PAN Yue-yin,SHEN Xia-bo.Meta-analysis of Short-term Efficacy of Neoadjuvant Endocrine Therapy and Neoadjuvant Chemotherapy in Breast Cancer[J].Journal of Medical Information,2020,33(16):67.[doi:10.3969/j.issn.1006-1959.2020.14.020]
[13]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(16):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[14]周靖宇,单慧明,成官迅.基于支持向量机的全乳纹理分析预测乳腺癌新辅助化疗疗效的价值[J].医学信息,2022,35(19):60.[doi:10.3969/j.issn.1006-1959.2022.19.016]
ZHOU Jing-yu,SHAN Hui-ming,CHENG Guan-xun.Prediction of Neoadjuvant Chemotherapy Outcomes of Breast Cancer Based on Whole Breast Texture with Support Vector Machine[J].Journal of Medical Information,2022,35(16):60.[doi:10.3969/j.issn.1006-1959.2022.19.016]
[15]杨季春,卿伯华,杨民正.动态增强MRI预测乳腺癌新辅助化疗后病理完全缓解的准确性[J].医学信息,2024,37(22):102.[doi:10.3969/j.issn.1006-1959.2024.22.025]
YANG Jichun,QING Bohua,YANG Minzheng.Accuracy of Dynamic Contrast-enhanced MRI in Predicting Pathological Complete Response After Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2024,37(16):102.[doi:10.3969/j.issn.1006-1959.2024.22.025]
[16]樊 婷,刘新兰２.乳腺癌组织中TOP2A蛋白表达临界值及其与蒽环紫杉类新辅助化疗疗效相关性研究[J].医学信息,2025,38(01):79.[doi:10.3969/j.issn.1006-1959.2025.01.014]
FAN Ting,LIU Xinlan.Critical Value of TOP2A Protein Expression in Breast Cancer Tissues and its Correlation with the Efficacy of Anthracycline Neoadjuvant Chemotherapy[J].Journal of Medical Information,2025,38(16):79.[doi:10.3969/j.issn.1006-1959.2025.01.014]